

Trust Headquarters  
Russells Hall Hospital  
Dudley  
West Midlands  
DY1 2HQ

**Ref:** FOI-072025-0001715

**Date:** 25.7.25

**Address / Email:**

Dear

**Request Under Freedom of Information Act 2000**

Thank you for requesting information under the Freedom of Information Act 2000.

Q1. In the last 6 months, how many patients have been diagnosed with Diffuse Large B Cell Lymphoma (DLBCL)? - **11**

Q1a. Of these patients, how many commenced treatment at your trust within the last 6 months? - **8**

Q2. In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL) with the following treatments:

R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone) - **4**

R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone) - **3**

Pola-BR (polatuzumab vedotin with rituximab and bendamustine) - **1**

Pola-R-CHP (Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin hydrochloride, and prednisolone) - **8**

R-CODOX-M (rituximab, cyclophosphamide, vincristine, doxorubicin and methotrexate) - **0**

R-IVAC (rituximab, ifosfamide, etoposide and cytarabine) - **0**

R-GCVP (Rituximab, gemcitabine, cyclophosphamide, vincristine, prednisolone) - **0**

(DA)-EPOCH +/-R (Prednisolone, doxorubicin, vincristine, etoposide, cyclophosphamide, rituximab) - **2**

R-GemOX (rituximab, gemcitabine and oxaliplatin) - **0**

Axicabtagene ciloleucel - **0**

Tisagenlecleucel - **0**

Epcoritamab - **1**

Loncastuximab tesirine - **1**

Glofitamab - **1**

Any other SACT - **5**

Stem cell transplant or bone marrow transplant (autologous or allogeneic)

Q3. In the last 6 months, how many patients have received the following 2nd line treatments for Diffuse Large B Cell Lymphoma (DLBCL):

Axicabtagene ciloleucel (Yescarta) - **0**

Tisagenlecleucel - **0**

Pola-BR (polatuzumab vedotin with rituximab and bendamustine) - **1**

R-GemOX (rituximab, gemcitabine and oxaliplatin) - **0**

Stem cell transplant or bone marrow transplant (autologous or allogeneic) - **0**

Any other treatments - **7**

Q4. In the last 6 months, how many patients has the Trust treated for 3rd line Diffuse Large B Cell Lymphoma (DLBCL)? - **2**

Q5. In the last 6 months, how many patients have you referred to other trusts for the treatment of Diffuse Large B Cell Lymphoma (DLBCL) for the following treatments:

CAR-T Therapy (E.g. Axicabtagene ciloleucel) - **0**

Stem cell transplant or bone marrow transplant (autologous or allogeneic) - **0**

Any other treatment - **0**

If you are dissatisfied with our response, you have the right to appeal in line with guidance from the Information Commissioner. In the first instance you may contact the Information Governance Manager of the Trust.

Information Governance Manager  
Trust Headquarters  
Russell's Hall Hospital  
Dudley  
West Midlands  
DY1 2HQ  
Email: [dgft.dpo@nhs.net](mailto:dgft.dpo@nhs.net)

Should you disagree with the contents of our response to your appeal, you have the right to appeal to the Information Commissioners Office at.

Information Commissioners Office  
Wycliffe House  
Water Lane  
Wilmslow  
Cheshire  
SK9 5AF  
Tel: 0303 123 1113  
[www.ico.org.uk](http://www.ico.org.uk)

If you require further clarification, please do not hesitate to contact us.

Yours sincerely

**Freedom of Information Team**  
**The Dudley Group NHS Foundation Trust**